|
The indications for the use of aspirin in primary
cardiovascular prevention continue to be a source of
intense debate, with major international guidelines
providing conflicting advices.
A new document, written by delegates of the main
Italian scientific societies dealing with
cardiovascular prevention and modeled on a similar
document by the European Society of Cardiology
Working Group on Thrombosis, reviews the evidence in
favor and against the use of aspirin therapy in
primary prevention based on data cumulated so far,
including recent data linking aspirin with cancer
protection.
While awaiting the results of several ongoing
studies, this document argues for a pragmatic
approach to the use of low-dose aspirin in primary
cardiovascular prevention, and suggests its use in
patients at high cardiovascular risk, defined as =2
major cardiovascular events (death, myocardial
infarction, or stroke) projected per 100
person-years, who are not at increased risk of
bleeding.
For more information
Siprec
Società italiana per la prevenzione cardiovascolare
Link...
MDN |